Loading the company…
Loading the company…
㈜리뉴메디칼
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2012. Industry: Wholesale & Retail. Revenue for 2025 was ₩20.9bn. It has 38 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2024-09-11 · latest registration 2022-07-22 · newest first
본 발명은 치주조직 및 골조직 유도 재생술을 위한 차폐막에 관한 것으로서, 폴리락트산계 폴리머와 젤라틴의 전기방사 막으로, 폴리락트산계 폴리머가 전기방사막의 매트릭스이고, FT-IR 스펙트럼 분석시 1640 cm -1 및 1542 cm -1 에서 아미드기(amide group) 피크가 검출되며, 젤라틴이 생분해성 속도를 제어하는 매개체로 작용하는 차폐막을 제공하며, 이는 그 구조적인 특성 및 젤라틴 농도가 습식 기계적 특성 및 생분해성의 매개변수로 작용함으로써, 우수한 기계적 특성, 수분흡수능력, 친수성, 생분해성, 세포 독성, 세포 증식 및 시험관 내 세포 생존력 등이 우수한 치주조직 및 골조직 유도재생술의 차폐막으로 유용하다.
본 발명은 3D 프린팅을 이용한 유치, 크라운 제조방법으로서, 인상용 트레이에 인상재를 투입하여 치아 모형을 본뜨는 단계;를 포함한다.
본 발명은, 병원 또는 개원의가 소지하고 있는 단말기; 및 상기 단말기에 의료 상담을 위한 콘텐츠를 제공하기 위한 서비스제공모듈부;를 포함하는 의료용 상담 시스템을 제공한다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 3 of 3 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 17.3 | 20.9 |
| Cost of sales | 12.5 | 15.4 |
| Gross profit (loss) | 4.7 | 5.5 |
| Selling, general and administrative expenses | 3.3 | 4.1 |
| Operating income (loss) | 1.4 | 1.5 |
| Non-operating income | 0.1 | 0.1 |
| Other gains | 0.0 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Other | 0.0 | 0.1 |
| Non-operating expenses | 0.4 | 0.3 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.3 | 0.3 |
| Other | 0.1 | 0.0 |
| Profit (loss) before tax | 1.1 | 1.3 |
| Income tax expense | 0.0 | 0.2 |
| Net income (loss) | 1.1 | 1.1 |
Revenue ₩20.9bn, up 21.3% YoY.
Operating margin 7.0% (prior 8.3%).
Net income ₩1.1bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06